Mueller SW, Molina KC, Blass B, Gibson C, Kohler AD, Krsak M, Wiktor AJ. Bone and
Skin / Subcutaneous Tissue Concentrations of Cefiderocol During Treatment of Extensively Drug Resistant Pseudomonas aeruginosa.
J Burn Care Res 2024:irae026. [PMID:
38422368 DOI:
10.1093/jbcr/irae026]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Indexed: 03/02/2024]
Abstract
Pyoderma gangrenosum is a rare dermatologic disorder that disrupts the skin barrier, requiring immunosuppressive therapy. We successfully used cefiderocol for the treatment of an extensively drug-resistant Pseudomonas aeruginosa bacteremia, and presumed osteomyelitis in a patient with severe pyoderma gangrenosum and associated immunosuppressive therapy while being medically optimized for skin grafting. We obtained bone and skin / subcutaneous tissue while the patient was on cefiderocol under an institutional review board approved biologic waste recovery protocol. Cefiderocol concentrations in bone and skin / subcutaneous tissue were 13.9 and 35.9 mcg/g, respectively. The patient recovered from bacteremia and underwent autografting without further complications. Cefiderocol at approved dosing of 2 grams IV (3-hour infusion) every 8 hours resulted in bone and skin / subcutaneous tissue concentrations adequate to treat extensively drug resistant Gram-negative bacteria that remain susceptible to cefiderocol.
Collapse